These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

865 related items for PubMed ID: 23280345

  • 1. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model.
    Zhang Y, Ren G, Guo M, Ye X, Zhao J, Xu L, Qi J, Kan F, Liu M, Li D.
    Int Immunopharmacol; 2013 Feb; 15(2):199-205. PubMed ID: 23280345
    [Abstract] [Full Text] [Related]

  • 2. Chimeric anti-IL-17 full-length monoclonal antibody is a novel potential candidate for the treatment of rheumatoid arthritis.
    Bai F, Tian H, Niu Z, Liu M, Ren G, Yu Y, Sun T, Li S, Li D.
    Int J Mol Med; 2014 Mar; 33(3):711-21. PubMed ID: 24378614
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological efficacy of anti-IL-1β scFv, Fab and full-length antibodies in treatment of rheumatoid arthritis.
    Qi J, Ye X, Ren G, Kan F, Zhang Y, Guo M, Zhang Z, Li D.
    Mol Immunol; 2014 Feb; 57(2):59-65. PubMed ID: 24091292
    [Abstract] [Full Text] [Related]

  • 4. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegård D, van den Berg WB.
    Arthritis Res; 1999 Feb; 1(1):81-91. PubMed ID: 11056663
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model.
    Li Q, Ren G, Xu L, Wang Q, Qi J, Wang W, Zhou B, Han X, Sun C, Wu Q, Yu Y, Peng Z, Zheng S, Li D.
    Int Immunopharmacol; 2014 Jul; 21(1):119-27. PubMed ID: 24800661
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
    Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB.
    Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis.
    Chao CC, Chen SJ, Adamopoulos IE, Davis N, Hong K, Vu A, Kwan S, Fayadat-Dilman L, Asio A, Bowman EP.
    Autoimmunity; 2011 May; 44(3):243-52. PubMed ID: 20925596
    [Abstract] [Full Text] [Related]

  • 10. Fibroblast growth factor 21 (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway.
    Yu Y, Li S, Liu Y, Tian G, Yuan Q, Bai F, Wang W, Zhang Z, Ren G, Zhang Y, Li D.
    Int Immunopharmacol; 2015 Mar; 25(1):74-82. PubMed ID: 25601498
    [Abstract] [Full Text] [Related]

  • 11. The bispecific antibody aimed at the vicious circle of IL-1β and IL-17A, is beneficial for the collagen-induced rheumatoid arthritis of mice through NF-κB signaling pathway.
    Wu Q, Wang Y, Wang Q, Yu D, Wang Y, Song L, Liu Z, Ye X, Xu P, Cao H, Li D, Ren G.
    Immunol Lett; 2016 Nov; 179():68-79. PubMed ID: 27616043
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
    van Nieuwenhuijze AE, van de Loo FA, Walgreen B, Bennink M, Helsen M, van den Bersselaar L, Wicks IP, van den Berg WB, Koenders MI.
    Arthritis Res Ther; 2015 Jun 17; 17(1):163. PubMed ID: 26081345
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. IL-17 increases cadherin-11 expression in a model of autoimmune experimental arthritis and in rheumatoid arthritis.
    Park YE, Woo YJ, Park SH, Moon YM, Oh HJ, Kim JI, Jin HS, Baek SH, Kim GT, Lee JH, Cho ML, Kim SI.
    Immunol Lett; 2011 Oct 30; 140(1-2):97-103. PubMed ID: 21798287
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis.
    Hsu YH, Chang MS.
    Arthritis Rheum; 2010 Nov 30; 62(11):3311-21. PubMed ID: 20722035
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.